BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

Posted on by BIOVECTRA

BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BIOVECTRA Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BIOVECTRA completed the replacement of two 4,000L vessels used for small molecule synthesis.

“These vessels have been very important for advancing our clients’ programs into later-stage clinical trials,” said Matt Frizzle, BIOVECTRA’s Director of Business Development, CMO Services. “They are highly critical when larger quantities of Active Pharmaceutical Ingredients (APIs) are needed and, in particular, through commercial supply.” For earlier stages of research, BIOVECTRA operates several cGMP kilo labs, with access to reactors in the range of 30-800L.

Additionally, BIOVECTRA announced an enhancement of its analytical capabilities through the purchase of new equipment. “These investments help ensure our process development team has adequate control and specifications to meet regulatory requirements,” said Dr. Marc Sauer, BIOVECTRA’s Vice President of Research and Development.  BIOVECTRA’s suite of analytical equipment will be bolstered with the addition of two UPLCs and five HPLCs, two Charged Aerosol Detectors (CAD), two single quad mass detectors, a XRPD unit, an ICP-MS, a particle surface area and a DSC/TGA instrument.

Combined these investments were in the order of $1.5M, and were made to enhance BIOVECTRA’s overall API service offering to our global biotechnology and pharmaceutical partners.

About BIOVECTRA

BIOVECTRA is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BIOVECTRA has over 45 years of experience specializing in:

For more information about BIOVECTRA, please visit www.biovectra.com.

Media Contact

Jordan MacGregor

Marketing and Communications Manager

[email protected]

902-566-9116 ext. 6376

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors